Company Overview of Dafra Pharma International Ltd.
Dafra Pharma International Ltd. identifies and develops treatments against malaria and other neglected tropical diseases. The company manufactures and markets malaria treatments, branded generics, and consumer healthcare products for African patients. Its products include artemisinin based combination therapies, amoxicilline and clavulanic acid, ibuprofen, ciprofloxacine, paracetamol, ferric ammonium citrate, anaeban, dafravit, fortaline, amifer, pico, sania, and kinazol. The company caters to patients, prescribers, health professionals, hospitals, and government agencies. Dafra Pharma was incorporated in 1996 and is based in Turnhout, Belgium.
Founded in 1996
32 1 461 78 20
32 1 461 78 59
Key Executives for Dafra Pharma International Ltd.
Similar Private Companies By Industry
|Apotheek Delestre NV||Europe|
|Apotheek Moons NV||Europe|
|Apotheek Philips NV||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Dafra Pharma International Ltd., please visit www.dafra.be. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.